We examined the impact of adding sufentanil during anaesthesia induction with propofol on bispectral index values in elderly patients (≥ 65 years). Patients were randomly assigned to receive a target-controlled sufentanil infusion (effect-site concentration of 0.3 ng.ml
Introduction
Bispectral index (BIS, Aspect Medical System, Natick, MA, USA) is widely used for estimation of the depth of anaesthesia. In clinical studies, a large variability in BIS values at loss of consciousness has been observed [1] . Several factors may be responsible for this inconsistency, including age. In elderly patients (average age 78 years) receiving increasing doses of propofol, BIS values at loss of consciousness were shown to be about 30% higher compared with younger patients (average age 35 years) [2] . Another factor is the concomitant administration of an opioid with propofol. In middle-aged patients (average age 48 years), BIS values at loss of consciousness were shown to be significantly higher in those receiving sufentanil concomitantly with propofol compared with those receiving propofol alone [3] . The objective of this study was to evaluate, in elderly patients undergoing a step-wise propofol induction, the impact of concomitant administration of sufentanil on BIS values at loss of consciousness. Our hypothesis was that elderly patients receiving sufentanil would lose consciousness at higher BIS values compared with those receiving placebo. This may have an impact on how anaesthesia is performed in this group of patients.
Methods
This randomised, double-blind, placebo-controlled study was approved by the ethics committee of Geneva University Hospitals in 2011. The study is reported according to the CONSORT recommendations for the transparent reporting of randomised, controlled trials [4] . Patients aged ≥ 65 years, ASA physical status 2-3, scheduled for elective surgery requiring a general anaesthetic, able to read and understand the information sheet, and to sign and date the consent form, were enrolled. Written informed consent was obtained from all participants. Exclusion criteria included: significant cardiovascular disease (New York Heart Association grade ≥ 3); renal insufficiency (glomerular filtration rate ≤ 35 ml.min À1 ); body mass index > 30 kg.m
À2
; depression or psychiatric disorder; history of drug or alcohol abuse; oesophageal reflux or hiatus hernia; contra-indication to one of the study drugs; and participation in any clinical trial within 30 days.
The study was performed in the ear, nose and throat surgery and neurosurgery unit of the Division of Anaesthesiology at Geneva University Hospitals between February 2012 and November 2015. Patients were fasted at least 6 h before anaesthesia and did not receive any premedication. Standard monitoring included three-lead electrocardiogram, peripheral pulse oximetry, non-invasive blood pressure and capnography (Philips MP70/EGM/FMS, Eindhoven, Netherlands; Dr€ ager Fabius Tiro, L} ubeck, Germany). A cannula was inserted in the dorsum of a hand for Ringer's lactate and drug administration. During the study, patients were spontaneously breathing oxygen 4 l.min À1 through a facemask.
Patients were randomised to receive sufentanil (Sufenta â ; HUG, Geneva, Switzerland) or placebo using a target-controlled infusion (TCI) system (Base Primea, Fresenius-Vial, Brezins, France) and the pharmacokinetic model of Gepts et al. [5] . Sufentanil and matching placebo were prepared by the hospital pharmacy. The initial sufentanil effect-site concentration was 0.3 ng.ml
À1
. When 'steady state' was obtained (identical plasma and effect-site concentrations as predicted by the TCI model), the infusion rate was maintained for 10 min. Induction of anaesthesia with propofol was then commenced. Propofol infusions (Propofol-Lipuro â ; B Braun, Melsungen, Germany) were prepared by the anaesthetic team. Propofol was administered using a separate TCI system (Base Primea, Fresenius-Vial, Brezins, France) with the pharmacokinetic model of Schnider et al. [6, 7] . The initial propofol effect-site concentration was 0.5 lg.ml
. When identical predicted plasma and effect-site concentrations were reached, the infusion rate was maintained for 5 min to achieve 'steady state' and to perform the study measurements. The effect-site concentration was then increased by 0.5 lg.ml À1 and the new 'steady state' was again maintained for 5 min. This procedure was repeated until loss of consciousness. The 0-5 point Observer's Assessment of Alertness/ Sedation (OAA/S) scale was used to identify loss of consciousness (Table 1 ) [8] . A score of 5 corresponded to a fully awake state, a score of 0 to a completely unresponsive state. For this study, a score < 2 (absence of response to mild prodding or shaking) was regarded as loss of consciousness. When loss of consciousness was reached, the study was finished. To minimise observer bias, only two investigators (CL, CC) evaluated sedation scores. They were blinded to BIS values and drug concentrations throughout the study period. Bispectral index was displayed continuously using an Aspect VISTA monitor and Quattro XP electrodes (version 3.20, revision 2.03 Aspect Medical System, MA, USA). Electrode impedance was kept below 5 kO. The side of electrode placement (left or right temporal) was chosen at random.
At baseline (patient awake in supine position, eyes closed and in a quiet environment before administration of any study drug), BIS and OAA/S values, heart rate, non-invasive blood pressure, pulse oximetry and endtidal carbon dioxide were recorded. To avoid missing the time-point of loss of consciousness, OAA/S scores were assessed every minute (i.e. independent of the stepwise increase in propofol effect-site concentrations) as soon as the score had decreased to 4. To minimise interactions between verbal or tactile stimulation, BIS values were always recorded (average value during a 15-s observation period) before OAA/S assessment. Painful stimuli (trapezius squeeze) were not applied. Non-invasive arterial pressure and heart rate were recorded at baseline and every 5 min during drugs administration until loss of consciousness. The primary outcome was the BIS value at loss of consciousness (OAA/S < 2). Our hypothesis was that patients in the sufentanil group would lose consciousness at higher BIS values.
Secondary outcomes included BIS values after administration of the study drug (sufentanil vs. placebo) before administration of propofol, duration of induction (time period from the start of propofol administration to loss of consciousness) and propofol effect-site concentrations at loss of consciousness. Our hypotheses were that BIS values would decrease after the administration of sufentanil, and that sufentanil would shorten induction time and decrease the cumulative amount of propofol that was necessary to achieve loss of consciousness.
We used the Shapiro-Wilk test to determine the distribution of variables. We used the student's t-test or the Kruskal-Wallis test as appropriate (significance threshold, 5%). Based on previous analyses in young patients [2] , we assumed that elderly patients who received propofol and sufentanil concomitantly would lose consciousness at higher BIS values than those receiving propofol alone (mean BIS values expected with propofol alone 70 [2] ; average difference with sufentanil, 10 points (SD 15)). With a = 0.05 and b = 0.2, 35 patients per group were needed (two-sided test) to show that difference.
The hospital pharmacy of Geneva University Hospitals was responsible for randomisation and drug preparation. Study drugs (sufentanil, matching placebo) were prepared in identical 20-ml syringes. Randomisation to sufentanil or placebo was done in a 1:1 ratio. Investigators and participants were unaware of the content of the syringes used during the study; the label contained only a serial number and an indication that it was a study drug. Syringes were prepared and stored at room temperature, and were taken at random from a box before each procedure. Unmasking of the code was done only after statistical analysis of both groups.
In a post-hoc sub-group analysis, we examined the influence of sex on BIS values to see whether the difference in BIS values at loss of consciousness was greater in men or women. We used a stratified and multivariate analysis to determine if the interaction between sufentanil and sex was statistically significant.
Results
A total of 71 patients (sufentanil 35, placebo 36) were randomly assigned; all completed the study and were included in the final analyses (Fig. 1) . No safety issues, technical problems or incidents arose during the study. No patient experienced intra-operative recall evaluated at 24 h postoperatively by specific questioning (how was your induction period? do you remember anything from your anaesthesia? did you experience any unpleasant sensations postoperatively related to the anaesthesia procedure?). The characteristics of the patients receiving sufentanil and placebo were similar; 41% were women. The BIS values at baseline were also similar, p = 0.658 ( Table 2) .
The mean BIS value at loss of consciousness was higher in patients receiving sufentanil compared with those receiving placebo; mean difference À5.0 (95%CI À8.9 to À1.1), p = 0.013 (Table 3) .
After administration of sufentanil, the median BIS value remained similar in the two groups, although there was greater variability in patients receiving sufentanil (range 70-98) compared with those receiving placebo (87-98).
After administration of sufentanil, the OAA/S score decreased by 1 point (from 5 to 4) in five patients; this did not happen in any of the patients in the placebo group (p = 0.025).
The median duration of induction was shortened by about 11 min in patients receiving sufentanil compared with those receiving placebo (p = 0.0001) ( Table 3) . No episodes of respiratory depression necessitating manual ventilation were observed during the induction period. The propofol effect-site concentration at loss of consciousness was lower in patients receiving sufentanil compared with those receiving placebo; mean difference À0.87 (95%CI À0.61 to À1.13), p < 0.0001 (Table 3) .
There was a difference in BIS values at loss of consciousness in men (mean difference À7.3 (95%CI À11.8 to À2.6), p = 0.003) but not in women (À2.1 (À4.8 to 9.0), p = 0.534).
Discussion
Four main findings emerge from this study. First, at loss of consciousness, BIS values in elderly patients who received a sufentanil-propofol combination were significantly higher compared with patients who received propofol alone. Second, in awake elderly patients, sufentanil at analgesic effect-site concentrations did not significantly decrease BIS values but deepened the clinically evaluated level of sedation in some patients. Third, with sufentanil, effect-site concentrations of propofol at loss of consciousness were significantly lower than with placebo. Finally, the impact of adding sufentanil to propofol on BIS values at loss of consciousness was observed in elderly men only but not in elderly women.
In a previous trial, we had compared elderly with younger patients and showed that advanced age had an impact on BIS values at loss of consciousness [2] . In that study, only propofol was used for induction [2] . We concluded that the proposed 'safety limits' of BIS should be re-evaluated and adapted to the elderly population. In the present study, the concomitant administration of sufentanil during propofol induction in the elderly led to BIS values at loss of consciousness that were even higher than in elderly patients receiving propofol alone. These observations confirm that adding sufentanil to propofol limits the decrease in BIS at loss of consciousness. The observed difference was statistically significant and may be clinically relevant. The mean difference of five units has probably minimal impact on how anaesthesia is conducted in most clinical scenarios, but may have an impact on patient outcome. The questions then are which BIS values should be considered in the elderly to ensure 'adequate' depth of anaesthesia, and whether these values should be further adapted in elderly patients who are anaesthetised with a combination of sufentanil and propofol. These questions are important, knowing that overdosing of anaesthetics may have an impact on postoperative delirium [9] . Furthermore, our study reminds that the absolute BIS value is not as relevant as suggested by the manufacturer and depends on the specific situation, in this case the administration of a combination of a hypnotic with an opioid, and on the specific patient population, in this case elderly patients.
Scott et al. investigated BIS values at loss of response to commands in two groups [10] . Higher BIS values were observed in patients receiving a combination of remifentanil with propofol, compared with patients receiving propofol alone. In this study, loss of response to commands occurred at a mean BIS value of 74 in the remifentanil-propofol group and of 66 in the propofol alone group. These values were very close to the values observed in our study. These results suggest that the actual BIS value at which the patient loses consciousness is more important than the range of values promoted by the manufacturer. Target-controlled infusion may have an advantage in that it easily facilitates titration of anaesthesia induction and we should not try to keep BIS values within recommended limits, but rather adjust them to individual patient requirements [11] .
The analgesic concentration of sufentanil administered in this study had no impact on BIS values. It has been questioned whether BIS is able to measure the hypnotic effect of opioids [12] . Indeed, as Scott et al. pointed out, opioids are in general poor hypnotics and the analgesic concentrations of opioids have little influence on the electroencephalogram (EEG). It is believed that systemic opioids mostly act on subcortical structures, in particular the midbrain and the thalamus [13] . Recent studies, using functional magnetic resonance imaging, suggest that opioids have some effect on cortical structures, yet these areas concern primarily the posterior two-thirds of the brain, such as the insular cortex, the occipital cortex or the cerebellum [14] . Bispectral index records the EEG from three electrodes attached to the patient's forehead and temporal area, thus recording mostly events from anterior cerebral structures. This could explain the unsatisfactory detection of the sedative effect of opioids by processed EEG monitors. Post-hoc analyses suggested that the differences in BIS values at loss of consciousness between the sufentanil and placebo groups were statistically significant in men but not in women. Although this finding should not be over-interpreted since the study was not designed to investigate this specific issue, it is potentially hypothesis-generating. Sex differences in anaesthetic drug effects have been described before. For instance, women have been shown to have a 20-30% greater sensitivity to non-depolarising neuromuscular blocking agents as compared with men [15, 16] . It has also been postulated that in men, the dose of propofol should be reduced by 30-40% compared with women to achieve comparable recovery times [17] . When using the propofol pharmacokinetic model of Schnider et al. that takes into account sex [6, 7] , blood concentrations are likely to be 10% lower in women compared with men [17] . These differences may be explained by differences in physiological parameters influencing the pharmacokinetics of propofol as, for example, volume of distribution or cardiac index. Over the past few decades, much work has focused on sex differences in the function of the central nervous system. Sex differences in electrical activity parallel to anatomical differences have been observed in the suprachiasmatic nucleus, considered as the 'biological clock' of the body [18] . Until now the influence of sex on processed EEG monitors has not been well understood.
Although there was an attempt to minimise observer bias through a double-blind design, our study suffers from some limitations. For instance, the OOA/S scale [8] , which is widely-accepted and used in clinical studies to evaluate the levels of consciousness, is prone to subjectivity. The study was designed to look at BIS values and not at recall. However, this complication cannot be completely excluded even if this was not highlighted during postoperative interviews. Study drugs were prepared by the hospital pharmacy in standard 20-ml polypropylene syringes and stored at room temperature. Even if expiration dates were strictly respected, it cannot be ruled out that sufentanil concentrations in these syringes changed, as described before [19] . It remains unknown how this may have affected the results of our study. Finally, observations were limited to the induction period and the results should be interpreted cautiously and should not be extrapolated to real surgical conditions with nociceptive stimuli that ideally are obtunded with higher doses of an opioid, for example, sufentanil rather than with increasing doses of propofol.
For administration of propofol, we used the pharmacokinetic model of Schnider et al. [6, 7] . Several propofol TCI models exist. They differ from each other by various pharmacokinetic parameters, one of which is blood-brain equilibration rate constant (k eO ). This constant describes how fast the effect-site concentration (in the brain) of propofol is obtained [20] and the Schnider model can result in over-prediction of effect-site concentration. Glen and White showed this in their study where a positive bias (measured concentration of propofol > predicted) was observed during almost the entire study period [21] . They also emphasised that, during steady-state conditions, positive or negative biases decreased the difference between the measured concentrations and the estimated effect-site concentrations of propofol. The prolonged steady state applied in our study (five supplementary minutes after the steady state was displayed on the screen) may also have improved accuracy, and decreased the risk of bias [22] .
We did not stratify patients into different age groups to see whether the effect of the opioid depended on age within this cohort of elderly patients. The minimum age for inclusion (65 years) may be regarded as too low when studying an elderly population. We choose this age limit to be consistent with our previous study [2] . Today, many patients undergoing surgery may be 20-30 years older than this and this proportion will further increase in the future. Very old patients and those with pre-existing brain conditions are at risk for adverse cognitive postoperative outcome. A stratification of different age groups and their sensitivity to opioids during surgery should be further investigated. In addition, the effect of sex in this population should be explored.
In the elderly receiving sufentanil concomitantly with propofol for induction of anaesthesia, BIS values at loss of consciousness are higher than those receiving propofol alone. The difference has probably little impact on how anaesthesia is conducted in most clinical scenarios, but may have an effect on patient outcome, especially in the elderly. This phenomenon may be more pronounced in men compared with women.
